Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH raised its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 388.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,288 shares of the biopharmaceutical company’s stock after purchasing an additional 12,157 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of Madrigal Pharmaceuticals worth $7,012,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its stake in Madrigal Pharmaceuticals by 9.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,860 shares of the biopharmaceutical company’s stock worth $1,168,000 after acquiring an additional 338 shares in the last quarter. Voya Investment Management LLC increased its stake in Madrigal Pharmaceuticals by 16.3% during the third quarter. Voya Investment Management LLC now owns 59,437 shares of the biopharmaceutical company’s stock worth $27,261,000 after purchasing an additional 8,347 shares during the period. Marex Group plc acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth about $548,000. Calamos Advisors LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth about $2,057,000. Finally, Gladstone Institutional Advisory LLC purchased a new position in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $501,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $480.45 on Monday. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $615.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26. The firm has a market capitalization of $10.91 billion, a PE ratio of -36.93, a price-to-earnings-growth ratio of 4.66 and a beta of -1.00. The business’s fifty day moving average price is $559.15 and its 200 day moving average price is $460.34.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Paul A. Friedman sold 24,800 shares of the stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $552.18, for a total value of $13,694,064.00. Following the transaction, the director directly owned 187,164 shares of the company’s stock, valued at $103,348,217.52. This trade represents a 11.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Richard S. Levy sold 8,500 shares of Madrigal Pharmaceuticals stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $520.96, for a total transaction of $4,428,160.00. Following the sale, the director owned 21,197 shares in the company, valued at $11,042,789.12. This represents a 28.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 123,436 shares of company stock valued at $65,479,642 over the last three months. 21.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Zacks Research lowered shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday. Canaccord Genuity Group boosted their target price on Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. The Goldman Sachs Group restated a “buy” rating and set a $571.00 price target on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. Finally, Piper Sandler lifted their price objective on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a research note on Friday, December 19th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $632.64.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.